November 1-15, 2014 Nov 6, 2014 {source}<div data-configid="5690019/10028657" style="width: 600px; height: 396px;" class="issuuembed"></div><script…
Life Sciences students trained by Biocon Academy ready to join industry Nov 6, 2014 The third batch of the Biocon Academy commenced on 3rd Nov’ at Bangalore
Glenmark enrols first patient for phase II trial of GBR 500 Nov 5, 2014 The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011
Ranbaxy obtains US FDA approval to market fenofibrate capsules Nov 5, 2014 Fenofibrate capsules are indicated for primary hypercholesterolemia and mixed dyslipidemia. In addition, it is indicated for…
Glenmark Generics receives final ANDA approval for Omeprazole DR capsules Nov 5, 2014 It is a generic version of Prilosec by AstraZeneca
Study confirms positive safety profile and effectiveness of Pradaxa in atrial fibrillation patients Nov 4, 2014 The US FDA Medicare study of 134,000 patients demonstrates benefits such as a significantly reduced risk of ischaemic stroke, a…
Phase III efficacy clinical study results of Sanofi’s Dengue vaccine candidate published Nov 4, 2014 Study successfully met primary objective and confirms high efficacy against severe dengue and hospitalisation
Multisorb Technologies appoints Peter Lirusso to Healthcare Packaging Group for Canada Nov 4, 2014 Lirusso brings vast experience in films, foils, and ridged plastics and blister packs within the pharmaceutical industry. And…
Biocon expands its strategic partnership with CytoSorbents Nov 4, 2014 Biocon will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the ICU as…
Indian Patent office issues new guidelines for pharmaceutical patent applications Nov 3, 2014 Generic disclosure in the prior art may not necessarily take away the novelty of a specific disclosure Taking into account the…